CLEVELAND, Ohio (October 20, 2026)—The dramatic success stories of GLP-1 weight loss medications are dominating the airwaves. Midlife women, who commonly experience weight gain resulting from menopause, have been especially drawn to the drugs. A new study suggests that hormone therapy is associated with greater and sustained weight loss with some GLP-1s. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—An estimated 44% to 60% of perimenopausal women report cognitive changes like forgetfulness and trouble concentrating—also known as brain fog. Despite the effect of these symptoms on quality of life and productivity, there is currently no FDA-approved pharmacological intervention. A new review suggests that ADHD medications may help. Study results will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Bone mineral density significantly decreases during and after menopause due to dropping levels of estrogen. Historically, estrogen therapy has been prescribed to help protect bones, but a new study suggests that the addition of testosterone therapy may improve results compared with using estrogen alone. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Premature menopause is associated with an increased risk of several long-term health problems due to estrogen deficiency. Cardiovascular disease (CVD) is one of those health risks. However, the underlying cardiometabolic causes are unclear. A new study suggests a possible connection with insulin levels. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—The menopause transition is often associated with genital changes, sexual discomfort, and urinary issues—symptoms that collectively are known as the genitourinary syndrome of menopause (GSM). Hormone and nonhormone treatments are available to manage these symptoms. A new pilot study explores histologic changes after microablative fractional radiofrequency. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Turnover related to menopause has become a critical global socioeconomic challenge, affecting female career longevity and organizational productivity. A new study suggests that, although many employers have attempted to make special accommodations in the workplace, they fail to address a woman’s increased psychological burdens related to the menopause transition. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Regular physical activity results in numerous health benefits. It has been shown to improve sleep, lower blood pressure, and reduce anxiety, while also building muscle, strengthening bones, and helping to control weight. A new study suggests it may also reduce an array of bothersome symptoms during perimenopause. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Postmenopausal women are at greater risk for multiple health issues, such as hip fractures and urinary tract infections (UTIs), due to estrogen loss. Vaginal estrogen is used to prevent recurrent UTIs, but a new study suggests its use may be associated with perioperative hip fracture complications, like UTIs. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.

CLEVELAND, Ohio (October 20, 2026)—Migraines are estimated to affect 10% to 29% of women during the menopause transition, when migraines often worsen and become more frequent, especially during perimenopause. This is due to unpredictable estrogen drops. A new study suggests postmenopausal women using hormone therapy will experience more frequent, longer-lasting migraines. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026.